TREM-1 as a biomarker in HER-2 negative breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at a protein called TREM-1 in your blood to see if it can help predict how well treatment works for HER-2 negative breast cancer. Researchers will check TREM-1 levels before and after neoadjuvant therapy (treatment given before surgery) and see how it relates to your cancer's response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman, 18 years or older
- You have been diagnosed with breast cancer that is HER-2 negative (either hormone receptor positive or triple negative)
- You are scheduled to receive neoadjuvant therapy (treatment before surgery)
- Your medical records must have complete information on your diagnosis, scans, and treatment plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This study collects small tissue samples from your breast cancer before, during, and after chemotherapy and immunotherapy to identify early signs of how well the treatment is working. The goal is to better predict treatment response and improve outcomes for patients with triple-negative or high-risk hormone-positive breast cancer.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This trial tests a combination of two drugs (trastuzumab rezetecan and toripalimab) given before surgery to treat a specific type of breast cancer that is hormone-receptor-positive and HER2-low. It aims to see if this treatment can improve outcomes for patients who have not had prior cancer treatment.
Hear when a new Breast Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.